Covid

COVID-19 has rekindled debate about pharmaceutical supply chains and prompted renewed calls for drug companies to source more active pharmaceutical ingredients (APIs) from the US and Europe. China is a major API, raw materials and intermediates supplier, and according to US Food and Drug Administration (FDA), 13% of the plants supplying APIs for US drugs are in China [1]. Likewise, many European pharmaceutical companies rely on China for APIs. Also, […]